GlassScriptPhysician profile
Edward J Prince
NPI 1659306975
$45,315.31
in general payments reported to CMS, 2019-2025
33 companies · $22K in 2025
The $22K reported for 2025 was more than what 92% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,963 · 2020: $1,818 · 2021: $6,873 · 2022: $1,779 · 2023: $5,580 · 2024: $427 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $2,494 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,000 · Travel and Lodging: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,000.00 |
| Food and Beverage | $2,494.07 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,000.00 |
| Travel and Lodging | $388.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Development Corporation | $33,545.28 | 2021-2025 | |
| Stryker Corporation | $9,556.76 | 2019-2025 | Triathlon, Mako, Tornier Perform Reversed Augmented Glenoid |
| Omnilife Science, INC | $682.45 | 2019-2021 | |
| Pacira Therapeutics, INC. | $467.71 | 2019-2021 | |
| Bone Support INC. | $144.45 | 2024 | Cerament G, Ceramentbone Void Filler |
| Total Joint Orthopedics, INC. | $98.23 | 2019-2025 | |
| Bioventus LLC | $86.72 | 2019-2023 | Exogen Ultrasound Bone Healing System, Durolane |
| Innovation Technologies INC | $76.04 | 2024-2025 | Irrisept |
| Depuy Synthes Sales INC. | $67.95 | 2019-2024 | Monovisc |
| Pfizer INC. | $62.80 | 2019 | |
| Nevro Corp. | $54.36 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $40.48 | 2019-2021 | |
| Kci USA, INC. | $35.85 | 2019-2020 | |
| Avanos Medical | $31.77 | 2023-2024 | On-Q* Pump and Accessories |
| Vericel Corporation | $29.76 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $29.60 | 2025 | |
| Sanofi-Aventis U.S. LLC | $29.26 | 2019 | |
| Lifenet Health | $28.34 | 2025 | Allograft Vmis Delivery System |
| Endo Pharmaceuticals INC. | $24.57 | 2022 | |
| Amgen INC. | $22.23 | 2025 | Krystexxa |
| Trice Medical, INC. | $20.38 | 2025 | |
| Horizon Therapeutics Plc | $19.42 | 2023 | Krystexxa |
| Endo USA, INC. | $18.99 | 2024 | Xiaflex |
| Medtronic, INC. | $16.52 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.28 | 2025 | |
| Maxx Orthopedics, INC. | $14.54 | 2019 | |
| Radius Health, INC. | $14.43 | 2020 | |
| Merck Sharp & Dohme LLC | $14.36 | 2019 | |
| Boston Scientific Corporation | $14.35 | 2021 | |
| Zimmer Biomet Holdings, INC. | $13.97 | 2025 | Persona |
| Innocoll Pharmaceuticals Limited | $13.49 | 2022 | |
| Spr Therapeutics, INC | $12.61 | 2022 | |
| Lilly USA, LLC | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.